What are the key principles and information regarding diabetes treatment, including critical points for insulin management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diabetes Management: Key Principles and Insulin Management

Symptoms and Pathophysiology

Classic symptoms of diabetes include increased thirst, frequent urination, headaches, blurred vision, and fatigue, which indicate uncontrolled hyperglycemia. 1

  • Type 1 diabetes results from autoimmune destruction of pancreatic beta cells, requiring exogenous insulin from diagnosis 2
  • Type 2 diabetes involves insulin resistance and progressive beta-cell dysfunction, with 90-95% of adult diabetes cases being type 2 3
  • Youth with type 2 diabetes typically present with obesity (BMI ≥95th percentile), strong family history, and substantial residual insulin secretion 4

Investigations and Monitoring

HbA1c should be monitored every 3 months, with treatment intensification if goals are not met. 4

  • Fasting plasma glucose (FPG) targets: 80-130 mg/dL (4.4-7.2 mmol/L) 5
  • HbA1c targets: <7% for most adults with type 2 diabetes; <6.5% for youth with type 2 diabetes due to lower hypoglycemia risk 4
  • Self-monitoring of blood glucose (SMBG) is required when taking insulin, initiating/changing treatment, not meeting goals, or during intercurrent illness 4
  • Daily fasting glucose monitoring is essential during insulin titration 5

Lifestyle Management

An individualized medical nutrition therapy program provided by a registered dietitian is recommended for all patients with diabetes. 4

Nutrition Therapy

  • Emphasize nutrient-dense foods with appropriate portions, focusing on vegetables, fruits, legumes, whole grains, and dairy products with higher fiber and lower glycemic load 4
  • Weight loss ≥5% through calorie reduction and lifestyle modification benefits overweight/obese adults with type 2 diabetes 4
  • Carbohydrate counting is essential for patients on flexible insulin therapy to determine mealtime insulin dosing 4
  • Avoid sugar-sweetened beverages and minimize foods with added sugars 4

Physical Activity

  • 60 minutes daily of moderate-to-vigorous exercise for children and adolescents 4
  • Limit nonacademic screen time to <2 hours daily 4
  • Include aerobic, muscle-strengthening, and bone-strengthening activities 4

Alcohol

  • Maximum one drink per day for adult women, two drinks per day for adult men 4
  • Chronic alcohol intake (45 g/day) causes deterioration in glucose metabolism 4

Initial Treatment Approach

Type 2 Diabetes in Adults

For adults with type 2 diabetes and HbA1c ≥9% or blood glucose ≥300-350 mg/dL with symptomatic/catabolic features, start basal-bolus insulin immediately at 0.3-0.4 units/kg/day. 5, 1

  • For HbA1c <9% without ketosis: Start metformin (titrate to 2000 mg/day) plus lifestyle modification 4
  • For HbA1c ≥9% without acidosis: Start metformin plus basal insulin at 0.5 units/kg/day 4
  • Metformin should be continued when adding insulin unless contraindicated, as it reduces weight gain, lowers insulin requirements, and decreases hypoglycemia risk 5, 2

Type 2 Diabetes in Youth

For youth with new-onset diabetes, obesity, and clinical suspicion of type 2 diabetes, the treatment algorithm depends on HbA1c and presence of acidosis. 4

  • HbA1c <8.5% without acidosis: Metformin plus lifestyle modification 4
  • HbA1c >8.5% without acidosis: Metformin plus long-acting insulin at 0.5 units/kg/day, titrated every 2-3 days based on blood glucose monitoring 4
  • Acidosis/DKA/HHS: Manage as type 1 diabetes with intravenous insulin until acidosis resolves, then subcutaneous insulin 4
  • Check pancreatic autoantibodies; if positive, transition to type 1 diabetes management 4

Type 1 Diabetes

All patients with type 1 diabetes require multiple daily injections or insulin pump therapy from diagnosis, with total daily insulin of 0.4-1.0 units/kg/day (typically 0.5 units/kg/day for metabolically stable patients). 5, 2

  • Approximately 50% as basal insulin and 50% as prandial insulin 5
  • Higher doses required immediately following ketoacidosis presentation 5

Insulin Initiation: Critical Points

When to Start Insulin

Insulin must be initiated immediately for patients with ketosis/DKA, random glucose ≥250 mg/dL, or HbA1c >9%. 4

Additional indications for insulin in type 2 diabetes: 5, 2

  • HbA1c ≥7.5% despite optimal oral medications
  • Blood glucose ≥300-350 mg/dL with symptomatic features
  • Acute illness, surgery, or pregnancy
  • Contraindications to or failure of oral medications

Starting Doses

For insulin-naive type 2 diabetes patients, start with 10 units once daily or 0.1-0.2 units/kg/day of basal insulin. 5, 6

  • For severe hyperglycemia (HbA1c ≥9%, glucose >300 mg/dL): Start basal-bolus regimen at 0.3-0.4 units/kg/day total, divided approximately 50% basal and 50% prandial 5, 1
  • Example for 86 kg patient with severe hyperglycemia: 13 units basal insulin (glargine) once daily at bedtime plus 4 units rapid-acting insulin before each meal 1
  • For hospitalized patients: 0.3-0.5 units/kg/day total daily dose, with half as basal insulin 5
  • High-risk patients (elderly >65 years, renal failure, poor oral intake): Use lower doses of 0.1-0.25 units/kg/day 5

Insulin Selection

Long-acting basal insulin analogues (glargine or detemir) are preferred for basal coverage, with rapid-acting analogues (lispro, aspart, glulisine) for prandial coverage. 5, 1

  • Analogue insulins are as effective as human insulin but associated with less postprandial hyperglycemia and delayed hypoglycemia 2
  • Glargine should not be diluted or mixed with other insulins due to low pH 5, 6

Insulin Titration: Critical Points

Basal Insulin Titration Algorithm

Increase basal insulin by 2-4 units (or 10-15%) every 3 days until fasting blood glucose reaches 80-130 mg/dL without hypoglycemia. 5

Specific adjustments based on fasting glucose: 5

  • FPG ≥180 mg/dL: Increase by 4 units every 3 days
  • FPG 140-179 mg/dL: Increase by 2 units every 3 days
  • FPG <80 mg/dL (>2 readings/week): Decrease by 2 units 5

Most patients can self-titrate by adding 1-2 units (or 5-10% for higher doses) once or twice weekly if fasting glucose remains above target. 5

When to Add Prandial Insulin

When basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day without achieving HbA1c goals despite controlled fasting glucose, add prandial insulin rather than continuing to escalate basal insulin. 5

Signs of "overbasalization" requiring prandial insulin addition: 5

  • Basal dose >0.5 units/kg/day
  • Bedtime-to-morning glucose differential ≥50 mg/dL
  • Hypoglycemia episodes
  • High glucose variability
  • Fasting glucose at target but HbA1c remains elevated after 3-6 months

Prandial Insulin Initiation

Start with 4 units of rapid-acting insulin before the largest meal or the meal causing greatest postprandial glucose excursion, or use 10% of current basal dose. 5

  • Titrate by 1-2 units or 10-15% every 3 days based on pre-meal and 2-hour postprandial glucose readings 5
  • Add to additional meals sequentially based on glucose patterns 5

Insulin Adjustment and Monitoring

Hypoglycemia Management

If hypoglycemia occurs, determine the cause and reduce insulin dose by 10-20% immediately. 5

  • Treat with 10-20 grams of oral glucose, which raises blood glucose by 40-60 mg/dL over 30-45 minutes 4
  • Increase monitoring frequency with changes in insulin dosage, concomitant drugs, meal patterns, physical activity, or in patients with renal/hepatic impairment 6
  • Signs of hypoglycemia may be reduced with beta-blockers, clonidine, guanethidine, and reserpine 6, 7

Monitoring Requirements

Daily fasting blood glucose monitoring is essential during titration, with reassessments every 3 days during active titration and every 3-6 months once stable. 5

  • Monitor HbA1c every 3 months 4
  • Assess adequacy of insulin dose at every visit, looking for signs of overbasalization 5
  • For patients on prandial insulin, monitor both fasting and postprandial glucose 5

Combination Therapy

Continue metformin when initiating or intensifying insulin therapy unless contraindicated, as it reduces weight gain, lowers insulin requirements, and decreases hypoglycemia risk. 5, 1, 2

  • Consider adding GLP-1 receptor agonist to basal insulin to improve HbA1c while minimizing weight gain and hypoglycemia risk 5
  • Discontinue sulfonylureas when starting multiple daily insulin injections to reduce hypoglycemia risk 1
  • Do not abruptly discontinue oral medications when starting insulin due to risk of rebound hyperglycemia 2

Administration Technique

Use the shortest needles (4-mm pen or 6-mm syringe needles) as first-line choice in all patients, as they are safe, effective, and less painful. 2

  • Administer subcutaneously into abdominal area, thigh, or deltoid at the same time each day 6
  • Rotate injection sites within given areas to reduce risk of lipodystrophy and localized cutaneous amyloidosis 6, 2
  • Avoid intramuscular injections, especially with long-acting insulins, as severe hypoglycemia may result 2
  • Do not inject into lipohypertrophic lesions, as this distorts insulin absorption 2

Follow-Up Schedule

Schedule follow-up within 2-4 weeks after insulin initiation to assess initial response, adherence, and side effects. 1

  • Reassess every 3 days during active titration 5
  • Once stable, follow-up every 3-6 months with HbA1c monitoring 5
  • More frequent monitoring required with treatment changes, intercurrent illness, or failure to meet goals 4

Critical Pitfalls to Avoid

Never delay insulin initiation in patients with severe hyperglycemia (glucose >300 mg/dL, HbA1c >10%), as oral agents alone will not achieve control. 1

  • Do not continue escalating basal insulin beyond 0.5-1.0 units/kg/day without addressing postprandial hyperglycemia, as this leads to overbasalization with suboptimal control and increased hypoglycemia risk 5
  • Do not start with basal insulin only in patients with severe hyperglycemia (glucose >300 mg/dL, HbA1c >10%), as both basal and prandial coverage are required from the outset 1
  • Do not wait longer than 3 days between basal insulin adjustments in stable patients, as this unnecessarily prolongs time to achieve glycemic targets 5
  • Do not ignore the need for prandial insulin when signs of overbasalization are present 5
  • Do not discontinue metformin when adding insulin unless contraindicated 5, 1
  • Do not rely solely on correction (sliding scale) insulin without scheduled basal and prandial components 5
  • Accidental mix-ups between insulin products can occur; instruct patients to check insulin labels before injection 6

Special Populations

Youth with Type 2 Diabetes

  • If initially treated with insulin and metformin and meeting glucose goals, insulin can be tapered over 2-6 weeks by decreasing dose 10-30% every few days 4
  • Consider adding GLP-1 receptor agonist or SGLT2 inhibitor approved for youth if HbA1c goals not met on metformin 4
  • Prioritize and maximize non-insulin medications to minimize weight gain before escalating insulin doses 4

Renal or Hepatic Impairment

  • Insulin requirements may need adjustment in patients with renal or hepatic impairment 6, 7
  • Use lower starting doses (0.1-0.25 units/kg/day) for high-risk patients 5

Pregnancy

  • Insulin is the primary treatment for diabetes during pregnancy 2
  • Patients should inform healthcare professionals if pregnant or contemplating pregnancy 7

References

Guideline

Management of Poorly Controlled Type 2 Diabetes with Hyperthyroidism

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

EADSG Guidelines: Insulin Therapy in Diabetes.

Diabetes therapy : research, treatment and education of diabetes and related disorders, 2018

Research

Lifestyle intervention: nutrition therapy and physical activity.

The Medical clinics of North America, 2015

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Initial Dosing for Lantus (Insulin Glargine) in Patients Requiring Insulin Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the best management approach for a patient with pre-diabetes, mildly elevated blood sugar, slightly elevated liver enzymes, obesity, and significant anemia?
What is the initial approach to managing a 26-year-old patient with newly diagnosed Diabetes Mellitus (DM)?
How to manage a 77-year-old male with long-standing Diabetes Mellitus, impaired renal function (eGFR 30), and elevated blood sugar (Random Blood Sugar Level 233) who is not currently on treatment?
What is the best initial management approach for a 60-year-old patient with hyperglycemia, elevated CRP, and a history of Diabetes Mellitus (DM), with negative complement levels and anti-dsDNA antibody, and no Urinary Tract Infection (UTI)?
What is the initial management approach for a 31-year-old with newly diagnosed diabetes?
What are the causes of pain in a patient with renal cell carcinoma (RCC) with liver metastases (mets) and peri-pancreatic lymph node involvement?
Is the bronchiectasis severity index applicable to cystic fibrosis (CF) bronchiectasis?
What is the preferred fluid choice for managing pancreatitis?
Is QOL-B (Quality of Life Questionnaire-Bronchiectasis) applicable to patients with cystic fibrosis who develop bronchiectasis?
What is the optimal management plan for a 45-year-old female patient with uncontrolled hypertension, GERD, and stage IIIa chronic kidney disease, currently on Losartan and Omeprazole?
What is the recommended dosage and administration of Malarone (atovaquone/proguanil) for malaria prophylaxis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.